Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics by Pincus, Steven M. et al.
Predicting response to leuprolide of women with premenstrual
dysphoric disorder by daily mood rating dynamics
Steven M. Pincusa,*, Shaista Alamb, David R. Rubinowc, Chaya G. Bhuvanesward, and Peter
J. Schmidtb
a990 Moose Hill Road, Guilford, CT 06437, USA
bBehavioral Endocrinology Branch, National Institute of Mental Health, Bethesda, MD, USA
cDepartment of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
dDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Abstract
Approximately 60–70 percent of women with premenstrual dysphoric disorder (PMDD) show
symptomatic improvement in response to the GnRH agonist leuprolide acetate, which suppresses
ovarian function. However, it has been very difficult to either predict or understand why some
women respond, while others do not. We applied several complementary statistical methods to the
dynamics of pre-treatment mood rating data to determine possible predictors of response for
women with PMDD. We compared responders (n = 33) to nonresponders (n = 12) in clinical trials
of leuprolide (three months in duration) as a treatment for PMDD, on the basis of pre-trial daily
self-ratings of sadness, anxiety, and irritability. We analyzed both sequential irregularity
(approximate entropy, ApEn) and a quantification of spikiness of these series, as well as a
composite measure that equally weighted these two statistics. Both ApEn and Spikiness were
significantly smaller for responders than nonresponders (P ≤ 0.005); the composite measure was
smaller for responders compared with nonresponders (P ≤ 0.002) and discriminated between the
subgroups with high sensitivity and specificity. In contrast, mean symptom levels were indistinct
between the subgroups. Relatively regular and non-spiky pre-trial dynamics of mood ratings
predict a positive response to leuprolide by women with PMDD with high probability, moreover
based on typically less than 3 months of daily records. The statistical measures may have broad
and direct applicability to behavioral studies for many psychiatric disorders, facilitating both
accurate diagnosis and the prediction of response to treatment.
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During the past 20 years, premenstrual syndrome (PMS) has been the subject of extensive
study. A severe form of PMS, premenstrual dysphoric disorder (PMDD), is a cyclical
disorder characterized by mood-related and somatic symptoms that occur during the luteal
phase of the menstrual cycle, disappear at or soon after the onset of menstruation, and are
associated with significant impairment of function. Approximately 3–8% of women
experience PMDD, which has been estimated as resulting in 14.5 million disability adjusted
life years annually in the United States (Halbreich et al., 2003; Johnson, 1987; Sternfeld et
al., 2002). The precise etiology underlying PMDD is presently unknown. However, physical
and behavioral symptoms are alleviated by suppressing ovarian activity (Brown et al., 1994;
Hahn et al., 1995) and can be provoked in medically ovariectomized women by exposing
them to exogenous gonadal steroids (Schmidt et al., 1998). Indeed, previous studies suggest
that 60–70 percent of women with PMDD respond to the GnRH agonist leuprolide acetate
(leuprolide) (Freeman et al., 1997; Mezrow et al., 1994; Mortola et al., 1991; Schmidt et al.,
1998). It has been, however, a major puzzle as to why some women respond, while others
do not.
The analysis of daily symptom ratings is a major component in the evaluation of PMS and
PMDD. Specifically, to certify PMDD, there needs to be a substantial (oftentimes 30%)
increase in mean levels of negative moods in the week before menses compared to the week
after the end of menses (American Psychiatric Association, 1994; Smith et al., 2003). Yet
for many PMDD women, there often appears to be a clearly defined cyclical regularity in
monthly ratings, beyond the requisite increase in mean negative emotions during the luteal
phase. However, apart from the mean of selected time-periods, other serial characteristics of
these mood rating sequences (time-series) and associated statistical measures generally
remain unevaluated.
In a previous study of mood rating time-series characteristics of PMDD and recurrent brief
depressive disorder (RBD) subjects, compared with each other and with normal controls, we
identified two primary distinct, complementary statistical attributes that allowed us to
statistically define each subgroup with high sensitivity and specificity, despite no differences
in mean mood levels among the subgroups (Pincus et al., 2008). The first attribute is
sequential irregularity (approximate entropy, ApEn), which identifies the existence and
degree of order and regularity (‘extent of pure cyclicity’) in what otherwise may be viewed
as random or disordered serial data. The second attribute, motivated by what appears to be
the defining characteristic of RBD, is the extent of brief sharp increases and decreases in
mood levels, quantified by a measure denoted ‘Spikiness’. As noted below, ApEn has been
widely applied throughout biology and medicine, including many studies of hormonal
dynamics of comparable data length and ‘noise’ (measurement inaccuracy) to those
encountered in mood rating studies. More recently, ApEn has also been applied to a mood
rating study contrasting three treatment regimens applied to healthy controls, with very
significant decrease in mood dynamic irregularity seen for one of the treatments, among the
regimens, despite no changes in mean levels (Yeragani et al., 2003), suggesting the utility of
ApEn to quantify relatively subtle changes in mood during therapy. Consequently, we asked
whether evaluation of pre-trial mood rating dynamics by ApEn and Spikiness in women
with PMDD who undertook a subsequent trial of leuprolide would provide enhanced
prediction of successful response to the therapy.
In the aforementioned study of mood rating dynamics of PMDD and RBD, we determined
that compared with the other subgroups, PMDD subjects exhibited less irregularity and
Spikiness, i.e., were smoother, more purely cyclical, and with fewer abrupt changes upwards
or downwards in their moods. Notably, as considered further in the DISCUSSION, prior
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studies (Freeman et al.,1997, 2004) have shown that womenwith PMDD or severe PMS
showed a poorer response to therapy if they exhibited mood dynamics that in the present
context equate to either several instances of significant off-menses spikes or substantial
deviations from cyclicity. Accordingly, the purpose of this study was to evaluate the
resultant hypothesis that smaller ApEn (greater regularity) and lower Spikiness of mood
ratings would predict successful response to leuprolide, while higher values of either or both
measures would predict unsuccessful response, concomitantly segmenting women with
PMDD into phenotypes based on their mood rating dynamics.
2. Materials and methods
2.1. Subject selection
Women with PMDD were self-referred in response to advertisements for women with
distressing premenstrual mood symptoms in local newspapers or referred by their physician.
All women were without current medical illness (as assessed by medical history, physical
examination, laboratory tests, and electrocardiogram) and medication free. PMDD was
prospectively confirmed by longitudinal ratings for three consecutive cycles. Before entry
into the study, prospective participants were screened with a daily visual-analogue scale
(VAS) of self-ratings of mood. All PMDD patients experienced at least 5 of the DSM-IV
symptoms for PMDD (American Psychiatric Association,1994) associated with significant
functional impairment; additionally, each PMDD patient in the present study showed at least
a 30% increase in mean levels (relative to the range of the scale employed) of negative
moods (sadness, anxiety, and/or irritability) in the week before menses compared with the
week after the end of menses in at least two of three menstrual cycles. Current and past
histories of psychiatric disorders were obtained with the SCID (Structured Clinical
Interview) for DSM III-R for women recruited prior to 1996, and with the SCID for DSM-
IV for those recruited during or after 1996 (Spitzer et al., 1990). PMDD subjects were not
permitted to have either a current or recent past (last two years) history of any disorder other
than PMDD.
Subjects for the current study were selected from patients seen in our clinic. Of the 274
women who met the aforementioned diagnostic criteria for PMDD between 1992 and 2008,
45 women were admitted to a trial of depot leuprolide as a treatment of PMDD, in either a
double blind placebo-controlled trial (n = 10) or an open label trial (n = 35). Thirty three
women (age = 38.8 ± 6.5 years) met our criteria for response, defined below, and twelve
women (age = 40.8 ± 5.3 years) did not meet the criteria.
All reported regular menstrual cycles (range, 21–35 days), and all had a negative urine
pregnancy test, normal thyroid levels, and a normal physical examination, including Pap
smear. None were on any hormonal based birth control at intake or at time of testing or
within the previous year. The protocols were reviewed and approved by the National
Institute of Mental Health (NIMH) institutional review board, and all subjects gave both
written and verbal consent to study participation.
Upon completion of screening and preceding the start of leuprolide, daily self-rating mood
data were recorded for 2–4 months. We utilized a 3-item visual-analogue scale (VAS) to
assess the severity of common symptoms of PMDD (Rubinow et al., 1984; Schnurr, 1988,
1989). The VAS forms were completed once daily (evening) during the three-month
baseline phase; the women were instructed to rate how they felt at the moment they were
completing the form. Herein, we analyze each of the sadness, anxiety, and irritability
symptom data sets as time-series. For each time-series, we evaluate the mean, irregularity
(ApEn), and extent of staccato variation (‘Spikiness’ statistic), the last two of which are
described below. In addition to the VAS, the women were asked to do Premenstrual Tension
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Syndrome Self Rating Scale (PMTS) cross-sectional ratings. In the 10-item scale used, a
rater assesses the severity of common symptoms of premenstrual syndrome on a 4-point
scale (with the exception of eating habits and sexual drive, which are evaluated on a 2-point
scale); a score of 0 indicates the absence of symptoms, and a score of 36 indicates that all
symptoms are present and severe (Steiner et al., 1980).
2.2. Leuprolide trial
The women in leuprolide trials made biweekly clinical visits to the NIH. The trial involved
injections of depot leuprolide acetate (3.75 mg) between days 2 and 6 after the onset of
menses for 3 months to evaluate the response of medically induced ovarian suppression.
Subjects who responded to leuprolide were continued for a second study phase during which
they received the GnRH agonist for an additional 3 months and were replaced with
physiological levels of estradiol and progesterone. For the purposes of this paper, we are
limiting the study to the effects of leuprolide alone. Further details can be found elsewhere
(Schmidt et al., 1998).
2.3. Criteria for response
Response to leuprolide was defined by both (i) the absence of significant symptom cyclicity
for each of sadness, anxiety, or irritability, and (ii) the absence of PMTS ratings >10 during
months 2–3 on leuprolide. To specify (i), significant symptom cyclicity was defined by a
symptom VAS score greater than 30% below the overall mean (during the symptomatic
baseline) which persisted for at least 2 consecutive days during months 2 and 3 of leuprolide
treatment. For (ii), symptoms were assessed by the 10-item PMTS ratings.
2.4. Hormonal, hot flush data
To assess further potential contributors to response, we measured hormonal and hot flush
data. For the former, blood samples were drawn every two weeks throughout the study. The
samples were centrifuged, and aliquots of plasma were frozen at −20 °C until the time of
assay (Schmidt et al., 1998). Plasma progesterone, estradiol, luteinizing hormone (LH) and
follicle stimulating hormone (FSH) were measured by radioimmunoassay as previously
described (Schmidt et al., 1998). For the latter, the women recorded the presence and
severity of hot flushes (a potential side effect of leuprolide) daily, employing a 6-point
likert-type scale (see Table 1).
Finally, clinical reports of the exacerbation of PMDD during the four weeks after leuprolide
administration (when administered in the early follicular phase) suggest that the initial
hormonal flare triggers symptoms in these women and could predict elimination of
symptoms when ovarian steroids are suppressed. Thus, we examined the relationship
between symptom exaggeration during the first month of leuprolide (i.e., symptom flare)
and response to leuprolide. A symptom flare was defined by the threshold values of anxiety,
irritability and sadness from the baseline mood ratings of patients before they started
leuprolide. The threshold value for each symptom was defined as the value obtained by
subtracting 30% of the range of VAS from the baseline mean of the particular symptom. A
flare was confirmed if any mood ratings exceeded the threshold values for two or more
consecutive days during the first month of leuprolide.
2.5. Analytic strategy
2.5.1. Quantification of irregularity—To quantify sequential irregularity, we utilize
approximate entropy, ApEn, a model-independent measure defined by Pincus (1991).
Primary mathematical and statistical properties of ApEn, including error estimation for
general processes and robustness to noise and artifacts can be found elsewhere (Pincus and
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Goldberger, 1994; Pincus and Huang, 1992; Pincus and Kalman, 1997; Pincus and Singer,
1996). ApEn was introduced to quantify regularity in sequences and time-series data,
initially motivated by applications to relatively short, noisy data (Pincus, 1991). It has been
used extensively to characterize the degree of randomness in a variety of applications that
explore regularity in physiological systems including patterns of hormonal secretion (Pincus
et al., 1998, 1999), heart rate (Pincus et al., 1993), respiration (Akay et al., 2002; Yeragani et
al., 2002) and EEG dynamics (Bruhn et al., 2000). Additionally, ApEn provides a direct
barometer of feedback system change in many coupled systems (Pincus, 1994; Pincus and
Keefe, 1992).
ApEn calibrates an extent of serial interrelationships, quantifying a continuum that ranges
from totally ordered to completely random. ApEn assigns a nonnegative number to a time-
series, with larger values corresponding to greater apparent process randomness (serial
irregularity), and smaller values corresponding to more instances of recognizable features or
patterns in the data. Two input parameters, m and r, must be specified to compute ApEn.
Briefly, ApEn measures the logarithmic likelihood that runs of patterns that are close (within
r) for m contiguous observations remain close (within the same tolerance width r) on next
incremental comparisons; the precise mathematical definition is given in Pincus (1991).
We calculated ApEn values for each time-series with input parameters m = 1 and r = 20% of
the standard deviation (SD) of the individual subject time-series, the standard choice for this
data length (Pincus and Goldberger, 1994; Pincus et al., 1999). Normalizing r to each time-
series SD gives ApEn a translation- and scale-invariance to absolute levels, in that it remains
unchanged under uniform process magnification, reduction, or constant shift higher or lower
(Pincus et al., 1993). Multiple previous studies that included both theoretical analysis and
clinical applications (Pincus, 1991; Pincus et al., 1999) have demonstrated that the input
parameters indicated above produce good statistical validity (reproducibility) for ApEn for
time-series of the length considered herein. Since the ApEn expected value increases slightly
with increasing series length, we control for this by analyzing (and reporting) ApEn values
calculated as a fraction of the maximal possible ApEn value for the given data length
(Veldhuis et al., 2008).
Below, ApEn is applied to both the raw data and to logarithmically transformed time-series,
as it was applied in our previous study (Pincus et al., 2008). The latter analysis, widely used
in many application areas, is complementary to the analysis of the raw data, as it generally
lessens the effects of steep local descents or ascents, of outliers, and of heteroscedasticity
(changing variance), while still preserving the relative order of the data.
2.5.2. Spikiness—A relatively subtle yet important difference between patient groups can
sometimes be seen by the presence or absence of acute sharp increases and decreases in
mood levels. We quantify the extent of such sharp changes by Spikiness, defined as the ratio
of the SD of the first differenced (incremental process) series and the SD of the original
series of mood ratings. Descriptively, Spikiness assesses the absolute magnitude of
incremental change or day-today variation of the original series, normalized (relative) to
overall variation. As discussed in Pincus et al. (2008), this formulation is both robust and
broadly applicable to general time-series, and to either linear or non-linear models.
This normalization to SD is consistent with other model-dependent formulations of
steepness of ascent near a peak such as kurtosis (Press et al., 1986) and crest factor
(Schoukens and Pintelon, 1991). Our preference for the specification of Spikiness, compared
to these thematically similar formulations, is dictated by several factors. First and primary,
both of these alternatives are intended for single peak or unimodal distributions, rather than
multiple peak or more general settings, and therefore are more limited in scope.
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Additionally, kurtosis is not always robust for shorter data sets, as it requires a fourth
moment estimate, while crest factor requires clear peak identification.
Mathematically, Spikiness and ApEn are defined to assess separate facets of dynamical
behavior in time-series. Generally, highly irregular data sets also tend to have high
Spikiness, but otherwise, both highly regular (low ApEn) and moderately irregular time-
series can exhibit either high or low Spikiness. This distinction between Spikiness and ApEn
is empirically seen in a previous study (Fig. 4 in Pincus et al., 2008).
The clinical utility of Spikiness is also seen in Pincus et al. (2008), in which patients with
recurrent brief depression had relatively large values of Spikiness, manifesting sharp
changes in state that underlie the brevity of the depression. This significantly contrasted with
lower values of Spikiness for women with PMDD, for whom the day-to-day mood variation
(hence the numerator in the Spikiness definition) is small relative to the overall SD for
patients in this subgroup.
2.5.3. Index of smooth cyclicity—Upon the quantifications by ApEn and Spikiness, we
have two complementary sets of statistics to assess deviations from purely cyclic curves
(e.g., sine waves). Since high values of either measure violate our perception of cyclicity, we
aimed to combine these two measures into a single, statistically appropriate index that
quantifies deviations from either regularity or smoothness. Accordingly, we combined ApEn
and Spikiness into a measure, denoted the Index of smooth cyclicity, by averaging equally
weighted values of ApEn and Spikiness (i.e., standardized to overall population ApEn and
Spikiness SDs). Irregular and spiky dynamics produce high index values, whereas regular
mood rating profiles with few large spikes produce low index values. We formed two such
indices, one based on ApEn calculated from the log-transformed series, the other from ApEn
calculated on the original series. Based on the previous study in which we applied ApEn to
both original and log-transformed data, we anticipated that the log-transformed version
would provide slightly better discrimination between subgroups, and thus might be more
likely to be applied in subsequent studies. Hence, and to distinguish between versions of this
index, below we denote the Index of smooth cyclicity as the averaged version incorporating
the log-transformed ApEn value, and refer to the other composite measure as the normalized
average of ApEn and Spikiness.
2.6. Statistical analysis
For each participant and statistic under study, in addition to calculating values for each
symptom, we also calculated the average value of the three individual symptom scores.
Notably, a low averaged value of the Index of smooth cyclicity typically manifests
consistency in both regularity and non-Spikiness across the three symptoms, throughout the
mood rating study period.
Statistical comparisons for discrimination between responder and nonresponder subgroups
(including demographic, hormonal and flare characteristics) were performed with both (i)
the two-sided t-test with unknown variance, and (ii) the nonparametric rank-sum test for
numerical data, and (iii) the chi-square test for categorical data. The application of both
parametric and nonparametric statistical techniques was chosen to insure robustness of the
results to a range of distributional assumptions. In particular, the individual subject
distributions for ApEn, Spikiness and the Index of smooth cyclicity appear to differ
considerably from a normal distribution (Fig. 1). Odds ratios were also calculated for
specified threshold levels. All findings were deemed significant at a 95% confidence level.
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None of the demographic or baseline characteristics were significantly different between the
responders and the nonresponders (Table 1). Specifically, there were no significant
differences between responders and nonresponders in the percentage of women who
experienced a clinically significant symptom exacerbation (flare) after the first injection of
leuprolide. Also, nonresponders did not report significantly more severe hot flushes than
responders, and measures of ovarian suppression, including plasma ovarian steroid levels
and gonadotropin levels, did not significantly differ between responders and nonresponders.
Thus, ovarian function in nonresponders was equally suppressed as that in responders, albeit
plasma gonadotropin levels, in particular, plasma LH, were non-significantly higher in the
nonresponders compared with the responders. Finally, although nonresponders had slightly
higher rates of a past history of major depression than did the responders, this difference did
not reach statistical significance.
Representative pre-trial daily mood rating time-series for two responders and two
nonresponders are shown in Fig. 2. For the responders, observe the ‘classic’ cyclic dynamics
for each symptom, whereas for the nonresponders, observe the inconsistency in mood
dynamics from month to month, and numerous brief moderate-to-large drops in mood, or
depressive epochs, not proximate to menses.
Table 2 indicates the mean ± SD for each of the six statistics under study (mean, Spikiness,
ApEn, ApEn of the log-transformed series, Index of smooth cyclicity, and normalized
average of ApEn and Spikiness) by subgroup, both averaged across the three VAS
symptoms (A) and for each individual symptom (B–D). Furthermore, Table 2 indicates the
sensitivity and specificity of each measure, with associated cutpoint (threshold), calculated
from receiver operating characteristic (ROC) curve analysis to maximize sensitivity plus
specificity. Individual subject values for each of these statistics by subgroup are displayed in
Fig. 1, for the data summarized in Table 2A.
There were no significant differences in mean levels between the responders and
nonresponders, P > 0.25 for both t-test and rank-sum test, for the aggregate (average of three
symptoms) measure and for each individual symptom. Each of the other measures were
significantly smaller for responders than nonresponders for virtually all other comparisons,
most pointedly realized for the comparisons based on averages of the individual (VAS)
symptom calculations (Table 2A), for which all non-mean comparisons showed differences
with significance P ≤ 0.006. The greatest significance was seen for the Index of smooth
cyclicity, P = 0.0012, with the cohort difference visually confirmed by Fig. 1(F).
For the Index of smooth cyclicity (for the averaged VAS symptom calculations), we also
calculated odds ratios for two distinct thresholds, one higher and one lower. For the higher
threshold, 7 of 12 nonresponders (58.3%) and 1 of 33 responders (3.0%) had index values
≥0.72 (Odds ratio, 44.8; 95% CI, 4.50 to 445.75; P = 0.001). For the lower threshold, 23 of
33 responders (69.7%) and 2 of 12 nonresponders (16.7%) had index values ≤0.62 (Odds
ratio, 11.5; 95% CI, 2.12 to 62.32; P = 0.004).
Finally, there were no significant correlations between mean levels and any of the other five
measures of temporal dynamics under study.
4. Discussion
The present analysis compares responders with nonresponders in leuprolide treatment of
PMDD, in a study cohort that includes, yet enlarges, the group of women evaluated in a
previous study (Schmidt et al., 1998). Seventy-three percent (33/45) of women responded to
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therapy, showing decrease of symptom severity and elimination of symptom cyclicity. This
response rate is slightly but insignificantly larger than that seen in previous studies (Freeman
et al., 1997; Mezrow et al., 1994; Mortola et al., 1991; Schmidt et al., 1998), and reaffirms
the efficacy of GnRH agonists in a majority of, but not all, women with PMDD.
4.1. Subgroup differences
The primary objective of the present study was to determine possible predictors of response
to leuprolide, based on VAS mood rating records obtained prior to onset of therapy.
Quantification of each of serial irregularity (ApEn) and the extent of brief, staccato
dynamics (Spikiness) in pre-trial mood ratings records enabled us to significantly
discriminate between responders and nonresponders. Furthermore, when the two
complementary statistics were combined into a single Index of smooth cyclicity, and
averaged across symptoms, an even more notable distinction emerged between the two
cohorts.
Very high index values were highly specific to nonresponse; similarly, very low index
values were very specific to response, quantified by the odds ratio calculations.
Descriptively, those subjects who were most consistently highly regular or cyclic in their
mood dynamics, across three symptoms and several months, and who also had few brief
spiky periods (negative or positive), showed responsiveness to leuprolide, while those
subjects at the other end of the statistical spectrum here responded poorly. The
quantification of a consistency of ‘purely cyclic’ symptomatology across the three axes
formalizes yet strengthens the clinician’s intuitive diagnosis of PMDD. Notably, we show
that such consistency, appropriately quantified, defines a phenotype that predicts very high
likelihood of therapeutic success with leuprolide.
There were no significant differences in mean sadness levels between responders and
nonresponders. This reinforces the utility of looking beyond the mean mood level to assess
affective state. This is not surprising – PMDD is an affective disorder defined by its
cyclicity as much as by associated symptoms. Hence, attempts to characterize this disorder
on the basis of mean or peak symptom levels fail to consider mood regulatory dynamics that
are essential to PMDD, and prompt the application of alternative statistical methods to
suitably quantify disrupted dynamics.
Although statistical comparisons disclosed significant differences between responders and
nonresponders for each of the three negative emotions, we realized clearest discrimination
upon averaging each of ApEn and Spikiness across the three symptoms (Table 2). This is
not unexpected. Although the DSM-IV mandates the presence of at least one (of four) core
symptoms, it does not specify the particular symptom(s), which often vary across women,
sometimes even across months for individuals. Thus our aggregate, averaged measures
ensure coverage of at least one symptom for all women, whereas no pre-specified mood
analyzed necessarily need exhibit substantial cyclic monthly variation.
There is a natural biologic interpretability to the relatively small ApEn values seen for the
PMDD subgroup. Clinically, the observation of premenstrual sadness followed by
postmenstrual euphoria provides a predictability or regularity to monthly dynamics,
commensurate with lower ApEn values, in contrast to a more stable baseline for normal
women, for whom mood variations are less tied to any specific fixed interval, appearing less
predictable, manifested by larger ApEn values (Pincus et al., 2008).
4.2. Clinical implications
Several methods have been developed to confirm the diagnosis of women with PMDD and/
or PMS (Angst et al., 2001; Freeman and Halbreich, 1998; Freeman et al., 1985; Yonkers et
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al., 1997). A protracted debate has accompanied the specification of diagnostic criteria, as
many women meeting criteria for severe PMS also meet criteria for PMDD. In brief, the
American Psychiatric Association espouses classification of PMDD as an affective disorder,
with primary symptoms the mood problems – uniform diagnostic criteria are listed in DSM-
IV (American Psychiatric Association, 1994). In contrast, the American College of
Obstetricians and Gynecologists provides diagnostic criteria for PMS (American College of
Obstetricians and Gynecologists, 2000), with greater emphasis on prominent somatic
symptoms. Both PMS and PMDD are defined largely, albeit not exclusively, on the basis of
mean level changes in specified attribute measures. Accordingly, the methods and results
reported herein may prove useful in specifying quantitative characteristics of mood and
physical dynamics of the disorder, either towards a single, unified severe form entity, or to
multiple distinct phenotypes that provide more precise syndromal classification for the
evaluation of treatment response. Above, we already realize a reduction in the heterogeneity
of treatment effects, an important concern in randomized controlled trials (Kent and
Hayward, 2007; Kravitz et al., 2004), upon restriction to phenotypes solely defined by either
very low or very high index values. Further fundamental understanding and potential utility
could be derived from associations between statistically defined phenotypes and (i)
dysregulation in concomitant physiological variables, and (ii) specific genotypes.
It is well known that symptom characterization and severity across menstrual cycles in
women with PMS are inconsistent (Schnurr,1988; Smith et al., 2003). In many studies of
PMS and PMDD, analyses are restricted to symptomatic cycles, which helps to decrease
cross-study variability (Angst et al., 2001; Smith et al., 2003). However, firm criteria to
certify individual cycles as symptomatic or asymptomatic are not definitive (Smith et al.,
2003), in part manifesting the lack of complete overlap between PMS and PMDD
specifications. A direct application of ApEn to an entire mood study record of at least
several months obviates an a priori need to assess or identify individual cycles as
symptomatic. Instead, such a direct application in effect assesses the degree of consistency
of symptomatic vs. asymptomatic cycles. Intermittently symptomatic women will generally
register higher ApEn scores than will consistently symptomatic women, marking the greater
mood irregularity. Indeed, one primary interpretation of the results above is that greater
consistency in symptomatic months in part defines a phenotype that is more likely to exhibit
positive response to leuprolide (and quite possibly to other similar medications). Moreover,
it is remarkable that we achieve the level of significance in comparisons herein based on
only 2–3 months of data per subject, although the simultaneous analysis of multiple
symptoms likely abets our present analyses. We anticipate that longer (e.g., 6 month) mood
rating studies, although somewhat less feasible, would provide yet finer definition of the
degree of monthly consistency of symptomatology and further precision in identifying
potential responders.
It is both striking and of considerable practical import that the statistically defined
distinctions were accomplished without either any incorporation of dates of menses or a
protocol mandate of a common start date with respect to menses. In effect, one of our
primary study conclusions is that for subjects with a low value of the Index of smooth
cyclicity, the native mood cyclicity itself is sufficiently well-defined that quantification of its
degree does not depend on cycle start-point, so long as two or more months of accurately
reported data are available.
The present findings reinforce the utility of daily recording of mood ratings during a study
period, since it is in analyses beyond mean level comparisons that we deduce the distinctions
seen here. In the absence of relatively accurate records, estimates of measures such as ApEn,
Spikiness, or other dynamic features would be considerably compromised, and accordingly,
so would the possibility of identifying proper phenotyping on the basis of these measures.
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Previous studies have disclosed a 60–70% efficacy rate of therapy for PMDD for GnRH
agonists (Freeman et al., 1997; Mezrow et al., 1994; Mortola et al., 1991; Schmidt et al.,
1998), and a 48–63% rate for selective serotonin reuptake inhibitors (SSRIs) (Freeman et al.,
2004) and for a low dose oral contraceptive pill (OCP) formulation containing drospirenone
3 mg and ethinyl estradiol 20 μg (Yonkers et al., 2005). Nonetheless, and importantly,
despite very distinct pharmacological strategies, in comparison studies, the rate of treatment
response has barely exceeded 20% above placebo (Halbreich, 2004), suggesting that only a
subgroup of women with PMDD respond to these medications. One primary potential
application of the present findings is the evaluation of phenotype-targeted treatments. We
hypothesize that the efficacy of the aforementioned (and possibly other) therapies will be
considerably larger than 20% above placebo treatment, when restricted to studies of PMDD
patients with a low Index of smooth cyclicity, i.e., those with regular and non-spiky
dynamics.
Further support for this hypothesis comes from reevaluation of previous studies in the
present context. Freeman et al also showed that patients either with a past history of
depression, or in a premenstrual exacerbation group with dysphoric symptoms throughout
the cycle, had a much lower response rate to leuprolide therapy, compared to a clearly
defined PMS subgroup (Freeman et al., 1997). Additionally, women with PMDD or severe
PMS who exhibited higher postmenstrual symptom levels (“a possible indication of
subclinical levels of depression”) showed a poorer response to sertraline treatment (Freeman
et al., 2004). In effect, co-mingled instances of acycylic depressive episodes or subclinical
dysphoric tendencies are predictors of poorer response, and a low Index of smooth cyclicity
implies that there are few instances of either ‘risk factor’, as assessed along two distinct
statistical axes. Thus many of the women in the aforementioned two studies with a reduced
likelihood of successful therapy would generally be excluded from a low Index of smooth
cyclicity cohort, on the basis of firm quantitative criteria. Finally, we remark that the
sertraline study (Freeman et al., 2004) utilized an SSRI, not a GnRH agonist, providing
further support that the identification of smoothly cyclic women with PMDD has potential
utility in the evaluation of a range of therapies across multiple pharmacological categories.
Finally, the negative findings in the comparisons of hormone levels are not surprising. It has
been well established that in many instances in which mean levels are unchanged,
disruptions in pulsatility patterns of hormonal dynamics provide primary characterization of
many (endocrinologic) pathologies, in part motivating the extensive application of ApEn to
this area of research (Pincus et al., 1996, 1998, 1999). Patients with PMS have previously
demonstrated altered secretory patterns of progesterone (Facchinetti et al., 1993) and LH
(Facchinetti et al., 1990). Notably, in a recent study of hypothalamic-pituitary-adrenal
(HPA) axis data in men with major depressive disorder (MDD), the depressed men had
significantly altered cortisol and ACTH ApEn compared with healthy controls, while
depressed patients and controls did not differ significantly on mean level indices of basal
hormone secretion (the latter consistent with prior studies) (Posener et al., 2004). Similarly,
despite little evidence of abnormal ovarian mean hormonal levels in PMS, there is
substantial evidence that gonadal steroids nonetheless trigger or play an important role in the
etiology of PMS (Muse et al., 1984; Rubinow et al., 1988; Schmidt et al., 1991).
4.3. Perspective and conclusion
Above, we have quantified two distinct, complementary statistical attributes of daily mood
rating dynamics to differentiate responders from nonresponders to leuprolide therapy in
women with PMDD, in the process providing enhanced phenotypic definition of this
disorder. Our study protocol fits into an orientation to better utilize extant or readily
obtainable data from women with PMDD, requiring a minimal burden and expense for the
subjects, over a relatively short (2–3 month) and typically quite feasible time course. The
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results here also validate the utility of relatively accurate record keeping of mood ratings on
a daily basis. Furthermore, upon delineation of PMDD into phenotypes on the basis of
regularity and Spikiness, we anticipate the possibility of considerably greater than the
present 20% ceiling in therapeutic response rate (above placebo) in the subgroup with
regular and non-spiky dynamics. Of course, future studies should be performed both to
confirm the present findings, and particularly to further specify this response rate.
The results are directly and immediately applicable to the prediction of response to
leuprolide therapy in women with PMDD. Finally, more broadly, the analytic methods
employed, which can typically be applied as a ‘black box’ statistical suite, have considerable
potential utility to studies of many mood disorders throughout psychiatry, either applied to
the present VAS or other mood rating scales, or to the dynamics of any of several
physiological signals.
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Individual subject values of responders and nonresponders for each of (A) mean; (B)
Spikiness; (C) ApEn; (D) ApEn of the log-transformed series; (E) normalized average of
ApEn and Spikiness; (F) index of smooth cyclicity (normalized average of ApEn of the log-
transformed series and Spikiness). R indicates responder, Non-R indicates nonresponder.
Each subject value is averaged over the three symptoms of the visual-analogue scale (VAS):
sadness, anxiety, and irritability.
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Representative pre-trial daily mood rating profiles for two responders and two
nonresponders. VAS sadness and irritability series for responder #1 are upper left, panels
(A, B); for responder #2, upper right, panels (C, D); for nonresponder #1, lower left, (E, F);
for nonresponder #2, lower right, (G, H). Timing of menses are indicated by dips in the
dotted marks displayed at the 0 level of each panel. Average values across all symptoms for
each statistic are: responder #1, mean, 60.58; Spikiness, 0.320; ApEn, 0.378; log-
transformed ApEn, 0.352; normalized average of ApEn and Spikiness, 0.354; Index of
smooth cyclicity, 0.340; responder #2; mean, 72.00; Spikiness, 0.557; ApEn, 0.501; log-
transformed ApEn, 0.292; normalized average of ApEn and Spikiness, 0.524; Index of
smooth cyclicity, 0.388; nonresponder #1; mean, 50.06; Spikiness, 1.024; ApEn, 0.873; log-
transformed ApEn, 0.820; normalized average of ApEn and Spikiness, 0.936; index of
smooth cyclicity, 0.894; nonresponder #2; mean, 46.21; Spikiness, 0.793; ApEn, 0.905; log-
transformed ApEn, 0.923; normalized average of ApEn and Spikiness, 0.858; Index of
smooth cyclicity, 0.876. On visual inspection, observe ‘classic’ cyclic dynamics for each
symptom for the two responders in (A, B) and (C, D). For each nonresponder, the mood
ratings sets (E, F) and (G, H) satisfy the quantitative criteria for PMDD. Yet note dynamic
inconsistency across months and between symptoms, greater irregularity, and greater
Spikiness, typically manifesting numerous brief moderate-to-large drops in mood or
depressive epochs not proximate to menses.
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Table 1
Demographic and baseline characteristics.
Characteristics Responders (n = 33) Nonresponders (n = 12)
Age (y) 38.8 ± 6.5 40.8 ± 5.3
BMI (kg/cm2) 25.5 ± 4.8 26.6 ± 4.8
No. Married (%) 16 (48.5) 4 (33.3)
No. with children (%) 22 (66.7) 6 (50.0)
No. with past major depression (%) 10 (30.3) 5 (41.7)
No. with symptom exacerbation (flare) after first injection of leuprolide (%)a 16 (48.5) 4 (33.3)
Severity of hot flushesb 2.7 ± 1.2 2.3 ± 0.8
Plasma hormone levelsc
Progesterone [ng/ml] 0.3 ± 0.2 0.3 ± 0.1
Estradiol [pg/ml] 20.9 ± 10.4 20.2 ± 12.7
LH [IU/L] 1.6 ± 1.6 3.0 ± 2.8
FSH [IU/L] 5.5 ± 3.2 7.6 ± 4.0
Statistical values given as mean ± SD for numerical variables and n (%) for categorical variables.
All comparisons between Responders and Nonresponders showed no statistically significant results, P > 0.05 for all comparisons.
a
A clinically significant symptom exacerbation was defined by the occurrence of a rating below a threshold level for two or more consecutive days
during the first month of leuprolide, for any symptom. The threshold level (for each symptom) was defined as the value obtained by subtracting
30% of the range of VAS from the baseline mean of the particular symptom.
b
The severity of hot flushes was recorded daily on a modified version of the 6-point likert-type rating scale, which measured the severity of
symptoms in which 1 = no symptoms, 6 = extremely severe symptoms. Values represent daily ratings during the last two weeks on leuprolide.
c
Values represent hormone levels during the last two months on leuprolide.
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